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2SUMMARY
Diagnostic trials evaluating a single marker or comparing two markers often employ an
arbitrary sampling ratio between the case and the control groups. Such a ratio is not
always an efficient choice when the goal is to maximize the power or to minimize the
total required sample size. Instead, optimal sampling ratios, discussed by Janes and Pepe
(2006), offer a better alternative for one-marker trials. In this paper we focus on com-
parative diagnostic trials which are frequently employed to compare two markers with
continuous or ordinal results. We derive explicit expressions for the optimal sampling
ratio based on a common variance structure shared by many existing summary statis-
tics of the receiver operating characteristic (ROC) curve. Estimating the optimal ratio
requires either pilot data or parametric model assumptions; however, pilot data are often
unavailable at the planning stage of diagnostic trials. In the absence of pilot data, some
distributions have to be assumed for carrying out the calculation. An optimal ratio from
an incorrect distributional assumption may lead to an underpowered study. We propose
a two-stage procedure to adaptively estimate the optimal ratio in comparative diagnostic
trials without pilot data or assuming parametric distributions. We illustrate the properties
of the proposed method through theoretical proofs and extensive simulation studies. We
use an example in cancer diagnostic studies to illustrate the application of our method.
We find that our method increases the power, or reduces the required overall sample size
dramatically.
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31. INTRODUCTION
Diagnostic trials estimate the diagnostic accuracy of a marker or compare the diagnos-
tic accuracy of two markers. For example, in a diagnostic trial by Hendrick and others
(2008), investigators compared the accuracy of digital mammography with screen-film
mammography. Pepe and others (2001) refer to these trials as phrase III diagnostic tri-
als. In these trials, the true disease status of subjects is known. To evaluate the diagnos-
tic accuracy of a binary marker, sensitivity and specificity are used. Sensitivity is the
probability of having a positive test result for a case subject. Specificity is the probabil-
ity of having a negative test result for a control subject. The false positive rate (FPR)
is 1−specificity. For continuous markers, we obtain sensitivity and false positive rate
(FPR) based on a threshold that distinguishes the test result as being positive or neg-
ative. A varying threshold allows a number of sensitivities and FPRs to be computed
simultaneously. The receiver operating characteristic (ROC) curve is a plot of sensitivity
versus FPR for all possible thresholds.
Typically the ratio between the number of cases versus the number of controls is fixed
in advance. Most diagnostic trials apply an equal case-control ratio; for example, a lung
cancer prevention trial recruited 71 prostate cancer cases and 71 age-matched controls
without cancer (Etzioni and others, 2003). A diagnostic study in Hendrick and others
(2008) compared the accuracy of digital mammography with screen-film mammogra-
phy using equal numbers of breast cancer patients and controls. In a colorectal cancer-
screening study, about the same number of colorectal cancer patients and non-cancer
subjects were used to identify markers (Janes and others, 2005). The equal ratio, how-
ever, may not be optimal in maximizing the test power or minimizing the total required
sample size. A procedure proposed by Janes and Pepe (2006) estimates the optimal ra-
4tio for evaluating a continuous marker. The ratio is optimal with regard to minimizing
the variance, or maximizing the power for a fixed total required sample size. Equiva-
lently, the optimal ratio minimizes the total required sample size with a fixed power.
To the best of our knowledge, their method is the first attempt to identify the optimal
sampling ratio in diagnostic trials. However, since the optimal ratio is derived using the
first derivative of the ROC curve, their method cannot be used for ordinal data which
often occur in medical imaging studies. More importantly, pilot data are required to
estimate the optimal ratio. In the absence of pilot data, some distributions have to be as-
sumed for carrying out the calculation. An optimal ratio from an incorrect distributional
assumption may lead to an underpowered study. In addition, optimal ratios for compar-
ative diagnostic trials are of interest to investigators, but have not been discussed in the
literature.
In this paper we derive the optimal sampling ratio of cases to controls in compara-
tive diagnostic trials. The proposed optimal ratio is based on a common variance struc-
ture shared among existing ROC summary statistics. Special cases of these statistics
include the nonparametric area under the ROC curve (AUC) statistic proposed by De-
Long and others (1988) and the weighted AUC statistic by Wieand and others (1989).
These statistics have been applied in the sequential diagnostic trial design by Mazum-
dar and Liu (2003) and Liu and others (2008). The calculation of the optimal sampling
ratio requires either parametric model assumptions or pilot data. When the parametric
model is incorrectly specified, the resulting ratio may not give the optimal power or the
minimal required sample size. It is desirable to re-calculate the optimal ratio when data
become available during the trial. We propose a two-stage method to incorporate the
idea of internal pilot data, reviewed in Proschan (2004). We assume a parametric model
5at the beginning of the trial to obtain the initial optimal ratio. This ratio is used to sample
the cases and controls at the first stage. When sufficient observations are available, the
optimal ratio is re-calculated at the second stage, and the numbers of cases and controls
are adjusted accordingly. We show that although the optimal ratio is updated during a
diagnostic trial, the analysis at the end of the trial can be carried out in the same fashion
as in the traditional trial without affecting the nominal type I error rate.
The paper is organized as follows. In Section 2, we start with the optimal ratio for
comparative diagnostic trials based on common ROC statistics. We then present the ex-
plicit expressions of the optimal ratios for comparing AUCs and for comparing weighted
AUCs. In Section 3, we propose a two-stage procedure to adaptively estimate the opti-
mal sampling ratio using the internal pilot data. We illustrate the power increase and the
savings on the overall required sample size using the proposed method through a cancer
example in Section 4. Section 5 investigates the small sample performance of the pro-
posed procedure in maintaining the nominal type I error rate and increasing the power.
Some discussion is presented in Section 6.
2. OPTIMAL SAMPLING RATIO
Suppose we have N subjects with m cases and n controls. Each subject is measured by
diagnostic test ℓ (ℓ = 1, 2). We define the ith case as Xℓi, where i = 1, . . . , m, and the
jth control as Yℓj, where j = 1, . . . , n. The joint cumulative survival functions for cases
are (X1i, X2i) ∼ Sd(x1, x2) and the joint cumulative survival functions for controls are
(Y1j , Y2j) ∼ Sd¯(y1, y2). Their marginal survival distributions are Xℓi ∼ Sd,ℓ(x) and
Yℓj ∼ Sd¯,ℓ(y) respectively. For the threshold c varying in (−∞,+∞), the sensitivity is
Sd,ℓ(c) = Pr(Xℓi > c), and the FPR is Sd¯,ℓ(c) = Pr(Yℓj > c). Subsequently, the ROC
6curve for test ℓ is defined as Rℓ(u) = Sd,ℓ(S−1d¯,ℓ (u)), where the FPR, u, falls within [0, 1].
Summary measures for a single ROC curve include the area under the ROC curve
(AUC), the partial AUC (pAUC), and the weighted AUC (wAUC). The AUC gives the
probability that a measurement randomly selected from the case group is greater than
the measurement randomly selected from the control group (Bamber, 1975; Hanley and
McNeil, 1982); that is, Pr(X > Y ) = ∫ 1
0
Sd
{
S−1
d¯
(u)
}
du. The wAUC by Wieand and
others (1989) is given by
Ω =
∫ 1
0
Sd
{
S−1
d¯
(u)
}
dW (u), (2.1)
where W (u) is a probability measure. We let W (u) be a point u0, a FPR, to calculate
the sensitivity of a test, or W (u) = u, where u ∈ (0, 1), to estimate the AUC. When
W (u) = (u− u0)/(u1 − u0), where u ∈ (u0, u1), (2.1) gives the partial AUC.
The statistics for comparing markers might be parametric, e.g., the binormal model
of Dorfman and Alf (1969), semiparametric (Zou and others, 1997; Tang and Zhou,
2009), or nonparametric (Mazumdar and Liu, 2003; DeLong and others, 1988; Han-
ley and McNeil, 1983; Wieand and others, 1989). Let θ be the parameter in the ROC
comparison, and θˆ be the estimator. Based on the variance expressions for these ROC
statistics, we identify the following common structure for the variance of all these ROC
statistics when the sample sizes get large:
var(θˆ) =
vx
m
+
vy
n
, (2.2)
where vx is the variance associated with measurements of case patients and vy is the
variance related to control patients. In this paper we use the nonparametric statistics
7by DeLong and others (1988) and Wieand and others (1989). We present the variance
expressions for these statistics in Section 2.1 and 2.2. One may refer to other aforemen-
tioned articles for the same variance structure of parametric and semiparametric ROC
statistics.
Given the variance structure in (2.2), the total required sample size in a diagnostic
trial can be minimized using an optimal sampling ratio when the variance is fixed. In
other words, the power for comparing two markers can be maximized using this optimal
sampling ratio. Suppose the total required sample size in the diagnostic trials is N =
m+ n, the sampling ratio is r = m/n. Let the variance of θˆ is a fixed constant, a. Since
m = rn = Nr/(1 + r), it follows that
vx/m+ vy/n =
1 + r
N
(vx/r + vy) = a.
The total required sample size can then be expressed as
N =
1 + r
a
(vx/r + vy).
To minimizeN , we take first derivative with respect to r and equate it to zero. We obtain
the following equation:
vy/a− vx/ar
−2 = 0.
By solving the equation above, the optimal sampling ratio is obtained as
r∗ =
√
vx
vy
. (2.3)
8The optimal sampling ratio is analogous to the Neyman allocation ratio for clinical trials
which has been widely used to save the overall sample size for a fixed power. Interested
readers can refer to Jennison and Turnbull (2000) and Rosenberger and Lachin (2002).
2.1 Optimal sampling ratio for comparing two continuous markers
The difference between two wAUCs, ∆ = Ω1 − Ω2, is used in Wieand and others
(1989) to compare the wAUCs for continuous data. Here the estimator Ωˆℓ of Ωℓ, for
ℓ = 1, 2, is obtained by substituting the empirical function estimators in (2.1). The
resulting ∆-statistic is given by ∆ˆ = Ωˆ1 − Ωˆ2. Let wi be
∫ 1
0
[Sd,1(S
−1
d¯,1
(u)) − I(X1i 6
S−1
d¯,1
(u)) − Sd,2(S
−1
d¯,2
(u)) + I(X2i 6 S
−1
d¯,2
(u))]dW (u), and let vj be
∫ 1
0
{R′1(u)[I(Y1j 6
S−1
d¯,1
(u)) − u] − R′2(u)[I(Y2j 6 S
−1
d¯,2
(u)) −u]}dW (u), Tang and others (2008) further
study the ∆-statistic and show that for large sample sizes, ∆ˆ is asymptotically equivalent
to
1
m
m∑
i=1
wi +
1
n
n∑
j=1
vj + (Ω1 − Ω2). (2.4)
Since wi’s are i.i.d. random variables corresponding to measurements of case patients
and vj’s are also i.i.d. random variables related to measurements of control subjects,
(2.3) gives the optimal ratio for comparing the difference between wAUCs:
r∗ =
√
var(wi)
var(vj)
, (2.5)
9where var(wi) is given by the following expression:
var(wi) =
2∑
ℓ=1
(∫ 1
0
∫ 1
0
Sd,ℓ{S
−1
d¯,ℓ
(s ∧ t)}dW (s)dW (t)−
[∫ 1
0
Sd,ℓ{S
−1
d¯,ℓ
(s)}dW (s)
]2)
−2
∫ 1
0
∫ 1
0
[
Sd{S
−1
d¯,1
(s), S−1
d¯,2
(t)}−Sd,1{S
−1
d¯,1
(s)}Sd,2{S
−1
d¯,2
(t)}
]
dW (s)dW (t),
and var(vj) is given by the following expression:
var(vj) =
2∑
ℓ=1
[∫ 1
0
∫ 1
0
R′ℓ(s)R
′
ℓ(t)(s ∧ t)dW (s)dW (t)−
{∫ 1
0
rℓ(s)sdW (s)
}2]
−2
∫ 1
0
∫ 1
0
R′1(s)R
′
2(t)[Sd¯{S
−1
d¯,1
(s), S−1
d¯,2
(t)} − st]dW (s)dW (t),
with the derivative of ROCℓ(u), R′ℓ(u) = S ′d,ℓ{S−1d¯,ℓ (u)}/S
′
d¯,ℓ
{S−1
d¯,ℓ
(u)}.
Since ∆ˆ compares AUCs, partial AUCs or sensitivities at a particular FPR, we discuss
the optimal ratios for these special cases by specifying corresponding weight functions.
When we let the weight function be W (u) = u, for 0 < u < 1, ∆ˆ compares the
AUCs. The optimal ratio in (2.5) implies that the following ratio between the case and
the control maximizes the power for comparing the AUCs:
r∗A =
√
vAx
vAy
,
where vAx and vAy have the following expressions as shown in the Appendix:
vAx =
2∑
ℓ=1
(
E[I(Xℓi > Yℓj)I(Xℓi > Yℓl)]− [E(I(Xℓi > Yℓj))]
2
)
−2(E[I(X1i>Y1j)I(X2i>Y2l)]−E[I(X1i>Y1j)]E[I(X2i>Y2l)]) ,
10
and
vAy =
2∑
ℓ=1
(
E[I(Xℓi > Yℓj)I(Xℓk > Yℓj)]− [E(I(Xℓi > Yℓj))]
2
)
−2(E[I(X1i>Y1j)I(X2k>Y2j)]−E[I(X1i>Y1j)]E[I(X2k>Y2j)]) .
The optimal ratio for evaluating one marker, say marker 1, is simply
√
E[I(X1i > Y1j)I(X1i > Y1l)]− [E(I(X1i > Y1j))]2
E[I(X1i > Y1j)I(X1k > Y1j)]− [E(I(X1i > Y1j))]2
.
Janes and Pepe (2006) derive this ratio in terms of placement values as
√
V ar(Sd¯,1(Y1j))
V ar(Sd,1(X1i))
.
When W (u) = I{u = u0}, where 0 < u0 < 1, the ∆ˆ-statistic compares the sensitiv-
ities at the FPR u0. The optimal ratio in (2.5) reduces to
r∗s =
√∑2
ℓ=1 {Rℓ(u0)} − [Rℓ(u0)}]
2} − 2A∑2
ℓ=1 {R
′
ℓ(u0)
2 − [R′ℓ(u0)u0]
2} − 2B
,
where
A = Pr(X1i > G
−1
1 (u0), X2i > G
−1
2 (u0))−R1(u0)R2(u0)
and
B = R′1(u0)R
′
2(u0)[Pr(X1i > G
−1
1 (u0), X2i > G
−1
2 (u0))− u
2
0].
The optimal ratio for evaluating marker 1 at the FPR u0 is reduced to the ratio derived
in Janes and Pepe (2006) as
√
R1(u0)(1− R1(u0))/[u0(1− u0)]/R
′
1(u0).
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2.2 Optimal sampling ratio for comparing two ordinal markers
The variance of the ∆ˆ-statistic involves the first derivatives of the ROC curves. The
optimal ratio in (2.5) cannot be readily applied to the ordinal data which often occur
in radiology. In addition, the ∆ˆ-statistic does not allow for ties in marker observations.
We thus consider the nonparametric statistic by DeLong and others (1988) to obtain
the optimal ratio for comparing two ordinal markers which are usually two imaging
modalities in radiology. DeLong’s statistic estimates P (X1i > Y1j) − P (X2i > Y2j) +
[P (X1i = Y1j)− P (X2i = Y2j)]/2, and is given as:
∆ˆD =
1
mn
n∑
j=1
m∑
i=1
[ψ(X1i, Y1j)− ψ(X2i, Y2j)],
where ψ(Xℓi, Yℓj) = 1, for Yℓj < Xℓi; 1/2 for Yℓj = Xℓi; and 0 for Yℓj > Xℓi, for marker
ℓ, ℓ = 1, 2. Let ΩAℓ be P (Xℓi > Yℓj) + P (Xℓi = Yℓj)/2 for marker ℓ, and ΩˆAℓ be its
estimator. DeLong and others (1988) show that the large sample variance of ∆ˆD has the
form of var(∆ˆD) = vDx /m+ vDy /n, with
vDx =
1
m− 1
m∑
i=1
{
[
1
n
n∑
j=1
ψ(X1i, Y1j)− Ω̂
A
1 ]
2 + [
1
n
n∑
j=1
ψ(X2i, Y2j)− Ω̂
A
2 ]
2
− 2[
1
n
n∑
j=1
ψ(X1i, Y1j)− Ω̂
A
1 ][
1
n
n∑
j=1
ψ(X2i, Y2j)− Ω̂
A
2 ]
}
,
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and
vDy =
1
n− 1
n∑
j=1
{
[
1
m
m∑
i=1
ψ(X1i, Y1j)− Ω̂
A
1 ]
2 + [
1
m
m∑
i=1
ψ(X2i, Y2j)− Ω̂
A
2 ]
2
− 2[
1
m
m∑
i=1
ψ(X1i, Y1j)− Ω̂
A
1 ][
1
m
m∑
i=1
ψ(X2i, Y2j)− Ω̂
A
2 ]
}
.
Therefore, it follows from (2.3) that the ratio, r∗D =
√
vDx /v
D
y , maximizes the power for
comparing two ordinal markers.
3. A TWO-STAGE PROCEDURE TO OBTAIN THE OPTIMAL RATIO
One may assume a parametric model to obtain the variances and resulting optimal ra-
tios derived in the preceding section. When a parametric model is correctly specified,
the optimal ratio can be calculated from (2.3) for comparing ROC summary measures,
and the sample size to obtain a specified power can be subsequently derived. However,
if the parametric model is mis-specified, the calculated sample size may not give the
appropriate power. We calculated the optimal ratios for comparing the AUCs or pAUCs
from binormal and bi-exponential distributions. When comparing the AUCs, the optimal
ratio is close to 1 for a wide range of the correlation parameter values for bivariate nor-
mal distributions. This implies that equal sampling for two groups yields the maximum
power for a fixed total required sample size. However, the optimal ratio is around 1.5 for
bi-exponential distributions, indicating that sampling 50% more in cases than controls
yields the maximum power to detect a difference between markers. When comparing
the pAUCs, Figure 1 shows the optimal ratios for bivariate normal distributions. The
optimal sampling ratio varies from 0.94 to 1.03 when correlation coefficients between
13
two markers vary from −1 to 1. Based on these two examples, the mis-specification of
parametric models at the planning stage may lead to an incorrect optimal ratio.
Proschan (2004) introduces the concept of internal pilot data which often refers to
accumulated data after a trial is carried out for a certain period of time. To correct for the
model mis-specification at the beginning of the trial, we propose a two-stage procedure
to use internal pilot data after some observations are available during the trial. Suppose
the total required sample size N is fixed. Without loss of generality, we use a two-sided
test in the proposed procedure. The procedure is given in the following steps:
• Step 1: Specify a parametric model to obtain vx,0 and vy,0, and the resulting initial
optimal ratio, r∗0 =
√
vx,0/vy,0.
• Step 2: Use the ratio r∗0 together with vx,0, vy,0 in the following sample size for-
mula to calculate initial sample sizes m0 and n0 with power 1− β and the signifi-
cance level α:
m0 =
(zα/2 + zβ)
2(vx + r
∗
0vy)
∆21
, (3.1)
and n0 = N −m0, where ∆1 is the difference between ROC summary measures
under the alternative hypothesis.
• Step 3: After sufficient marker measurements are available on m1 cases and n1
controls at the first stage, the variance expressions of either the ∆-statistic (Wie-
and and others, 1989) or DeLong’s statistic (DeLong and others, 1988) are re-
calculated using available data. These variance estimators, vˆx,1 and vˆy,1, are ap-
plied in (2.3) to re-calculate the optimal ratio, rˆ∗ =√vˆx,1/vˆy,1.
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• Step 4: Continue the trial by recruiting M2 cases and N2 controls, where M2 and
N2 are given by
M2 =
Nrˆ∗
1 + rˆ∗
−m1 and N2 =
N
1 + rˆ∗
− n1. (3.2)
It is showed in Proschan (2004) that using the internal pilot data for comparing pop-
ulation means in clinical trials maintains the nominal type I error rate. The reason is that
the sample variance obtained at the end of the first stage does not give any information
for the sample mean at the end of the trial. The same relationship between the estimated
variance and the test statistic is also true for the ∆-statistic or DeLong’s statistic, as
stated in Proposition 1. The proof is provided in the Appendix.
Proposition 1: At the first stage when m1 and n1 get large, the variance estimated at the
first stage does not give any information for the ∆-statistic or DeLong’s statistic at the
end.
Proposition 1 shows that estimating variances and the resulting optimal ratio using
data from the first stage do not reveal information about the estimated difference between
two ROC statistics obtained at the end of the second stage. Thus, although the optimal
ratio is updated during the trial, the analysis at the end of the trial can be carried out in
the same fashion as in the trial without updating the optimal ratio. This is important in
maintaining the proper type I error rate.
4. EXAMPLE
In this section, we applied our method to a cancer diagnostic trial (Goddard and Hinberg,
1990). In this study 135 cancer patients and 218 non-cancer patients were recruited. A
15
traditional biomarker, A, and newly developed diagnostic biomarkers were used to test
blood samples from each subject. The unit of measurement was mmol of product per
minute per millilitre, IU/mm. Measurements are highly skewed for all the methods. We
compared a new biomarker D and the reference biomarker A to illustrate the power
increment and the sample size savings by using the proposed procedure. We assumed
a contrast of ∆1 = 0.05 between AUCs and the type I error rate 0.05 for power and
sample size calculation based on a two-sided alternative. At the first stage, we accrued
data on m1 = 60 cancer and n1 = 60 noncancer patients, and obtained the variance
estimates, vˆx,1 = 0.082 and vˆy,1 = 0.035, which resulted in the optimal case-control
ratio, rˆ∗ = 1.53, from (2.3). Let N be the overall sample size, which is 353 by summing
the numbers of cases and controls. Using this optimal ratio in the expression (3.2) in
Step 4 of the proposed procedure, the numbers of the cases and controls to be recruited
in the second stage were calculated to be 153 and 80, respectively. The power using the
optimal ratio was then 50.9% using the following equation:
1− β = Φ
(
∆1
√
Nrˆ∗
(1 + rˆ∗)(vˆx,1 + vˆy,1rˆ∗)
− zα/2
)
.
This power offers 7% increment over the power 43.8% calculated using the equation
above by replacing rˆ∗ with the original case-control ratio of 0.62. We also investigated
the savings on the overall sample size by using the proposed procedure. Using the orig-
inal power 43.8% with the estimated optimal ratio, rˆ∗ = 1.53, the overall sample size
was calculated to be to 292 with 177 cancer patients and 115 noncancer patients. This
offers savings of 61 patients over the original ratio.
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5. SIMULATION STUDIES
In this section, we demonstrated the performance of our method for maximizing power
when comparing summary statistics of diagnostic tests. We compared the proposed two-
step procedure with the equal case-control ratio and a fixed case-control ratio under three
parametric models. Three pairs of AUCs and pAUCs were specified in advance. We
used DeLong’s statistic for comparing the AUCs and the ∆-statistic for comparing the
pAUCs. We simulated 5000 observations from bivariate normal (BN), bivariate lognor-
mal (LN) and bivariate exponential (BE) distributions, respectively. The bivariate nor-
mal models had the forms of (X1, X2) ∼ N{(µ1, µ2),Σ} and (Y1, Y2) ∼ N{(0, 0),Σ},
where in the 2×2 matrix Σ, the diagonal elements are 1’s and off-diagonal elements are
ρ. We chose ρ = 0.1 and ρ = 0.25 in our simulations. µ1 and µ2 were computed accord-
ing to three pairs of AUCs, (0.70, 0.75), (0.75, 0.80) and (0.70, 0.80), respectively. For
comparing the pAUCs with the FPR in the range of (0, 0.6), (µ1, µ2) were used for three
pairs of pAUCs, (0.30, 0.35), (0.35, 0.40) and (0.30, 0.40), respectively. The bivariate
lognormal models had the forms of exp(X1, X2) and exp(Y1, Y2) for cases and controls,
respectively. They had the same values of (µ1, µ2) for the AUCs and pAUCs as above.
And then, according to the algorithm in Gumbel (1960), the bivariate exponential ran-
dom variables take the form H(x, y) = H1(x)H2(y)[1 + 4ρ{1 −H1(x)}{1 −H2(y)}],
where ρ ∈ [−0.25, 0.25]. We set ρ be 0.1 and 0.25 here. The marginal survival func-
tions for cases and controls were exp(−βℓ1x) and exp(−βℓ2y), so we could generate
data from these two distributions respectively. In the simulation, we set β11 = 1 and
β21 = 1. β12 and β22 were computed according to the AUC or pAUC values. For the
pairs of AUCs (0.70, 0.75), (0.75, 0.80), and (0.70, 0.80), the corresponding (β12, β22)
values were (2.333, 3.003), (3.003, 4.000) and (2.333, 4.000). For the pairs of pAUCs
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(0.30, 0.35), (0.35, 0.40) and (0.30, 0.40), the (β12, β22) values were (1.8957, 2.5094),
(2.5094, 3.3887) and (1.8957, 3.3887), respectively.
In our simulation, we first assumed that our samples were from bivariate normal
distributions, then used equation (3.1) to calculate the initial total required sample size.
With the type I error rate 0.05 and power 80%, the initial total required sample sizes were
N = 1421, 1200, or 326 to detect the difference of three pairs of AUCs of (0.70, 0.75),
(0.75, 0.80) and (0.70, 0.80), respectively, with ρ = 0.1. When ρ = 0.25, the total
required sample sizes, N = 1207, 1025, or 278, were needed to detect the difference
in these pairs. For comparing the pAUCs, the initial total required sample sizes were
N = 1067, 979, and 251, for for ρ = 0.1, and N = 915, 842 and 216 for ρ = 0.25.
There were three different sampling ratios: 1) the proposed two-stage optimal ratio; 2)
fixed sample ratio of 0.5; 3) equal sampling ratio. To implement the proposed method,
we defined the number of available observations at the first stage, m1 = n1 = N/4.
By substituting nonparametric variance estimates vˆx,1 and vˆy,1, the resulting optimal
ratio was estimated by rˆ∗ =
√
vˆx,1/vˆy,1, and M2 and N2 were calculated using (3.2).
We then generated M2 new observations for cases and N2 observations for controls.
Subsequently, the null hypothesis of equal AUCs or pAUCs was rejected in favor of the
alternative if the Z-statistic calculated using all simulated data was greater than or equal
to z0.025. The simulated power was then calculated as the percent of times out of 5000
that the null hypothesis was rejected. The simulated powers for all simulation settings
are present in Table 1.
Table 1 illustrates that larger correlations resulted in higher rejection rates. The sam-
pling ratio is another factor impacting the power when the alternative hypothesis is true.
For different underlying distributions, the proposed two-stage method has higher powers
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than the fixed ratios in most of the settings.
We also evaluated the performance of the two-step procedure to see whether the
procedure maintains the nominal type I error rate. We used the total required sample
sizes, N = 200, 400, or 500. The parametric distributions and three different sampling
ratios used in the previous simulation were considered. We assumed equal AUCs or
pAUCs with the AUCs being (0.70, 0.75, 0.80), and the pAUCs being (0.30, 0.35, 0.40).
The nominal type I error rate was 0.05 in our simulation. The simulated type I error rates
are shown in Table 2. All these rates are close to the nominal level when the sample size
goes to 500.
Variability in the estimators, vˆx,1 and vˆy,1, is associated with the initial sample sizes
at the first stage. Such variability affects the calculation of the optimal sampling ra-
tio, which may in turn have an impact on the power in the proposed procedure. We
conducted another simulation study to investigate the impact of the initial sample size
selection. We used the total required sample size of 400, and set the initial sample sizes
of cases and controls to be m0 = n0 = 50, 60, 80, or 100. Observations were simulated
from the binormal distributions with the difference of 0.05 between two AUCs. In each
simulation, the variance estimators for calculating the optimal ratio were estimated at
the first stage from three scenarios, namely, 1) a single set of m0 cases and n0 controls,
2) averaging variance estimates of 10 sets of m0 cases and n0 controls, and 3) averaging
variance estimates of 100 sets of m0 cases and n0 controls. Results based on 1000 repli-
cations for each setting are listed in Table 3. It indicates some variations in power for
the first scenario. When more datasets are involved in the calculation, power becomes
more stable regardless of the initial sample sizes. More importantly, Table 3 shows that
the initial sample size selection had little impact on the final power.
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6. CONCLUSION
The optimal sampling ratio in diagnostic trials can maximize the test power or minimize
the overall sample size. The optimal sampling ratio discussed in this paper is analogous
to the optimal allocation ratio in assigning patient treatments in clinical trials. The op-
timal allocation ratio has been used in clinical trials for decades, but the importance of
the optimal ratio in diagnostic trials has not been widely recognized. Implementation
requires the calculation of complicated variances of frequently used ROC statistics. This
paper discusses a common variance structure for ROC statistics, and thereby introduces
optimal sampling ratios in comparative diagnostic trials based on these statistics. Two
popular nonparametric ROC statistics are used to illustrate the explicit forms of the op-
timal ratios because their variance expressions can be written as the sum of separate
terms; one relates to the cases, and the other relates to the controls. The same variance
structure is shared by many existing parametric and semiparametric ROC statistics. This
implies that the optimal ratio form derived in (2.3) is also applicable to these existing
statistics.
When marker results follow normal distributions, the optimal sampling ratio is close
to 1 for many parameter settings. Then sampling the same number of cases and controls
can potentially achieve the maximal power for a fixed total required sample size. When
the marker results follow exponential distributions, the sampling ratio is close to 1.5. We
need to sample more cases than controls to gain power or reduce the overall sample size.
If preliminary studies are available before carrying out a comparative diagnostic trial,
the variance can be estimated using pilot data to obtain the optimal ratio for comparing
specified ROC summary measures. The ratio can then be used to recruit patients in
the trial, and re-calculating the ratio may not be necessary during the trial. However,
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when medical practitioners do not have preliminary data for the markers and are not
certain about the distributions of the marker results, the distribution assumption used
for obtaining the optimal ratio may be far from the true underlying distributions for the
marker results. This may result in less power or larger overall sample sizes than using the
true optimal ratio. The proposed two-stage procedure is then particularly useful to ensure
that the optimal ratio can be re-calculated using using internal pilot data during the
trial. The proposed procedure performed well in a large scale simulation study. We also
demonstrated that the proposed procedure maintains the nominal type I error rate in the
simulation. We used an example in cancer diagnostic studies to illustrate the application
of our method on maximizing the test power and saving overall sample sizes. The results
indicated that compared with the original sampling ratio, using the proposed two-stage
procedure for a fixed overall sample size increased the test power. Alternatively, for the
fixed test power, the proposed procedure reduced the overall sample size by nearly 25%.
It is sometimes desired to minimize the total cost in a diagnostic trial with a limited
budget. High cost may be associated with diagnostic trials considering using a gold
standard test to identify the subjects and using markers to diagnosing them. This is
particularly true in medical imaging diagnostic trials when expensive medical imaging
devices costing hundreds of dollars for a single session of scans are involved. A case may
cost more than a control because of higher expenses associated with providing necessary
medical care when classifying and diagnosing them. We may consider c1 and c2 as costs
related to a case and a control, respectively. Usually, c1 and c2 can be determined by
medical experts before conducting a trial. Then similar to the derivation in Section 2, the
optimal sampling ratio for minimizing the total cost is given by r∗c =
√
c2vx/c1vy for a
fixed power. This ratio reduces to the one derived in (2.3) when c1 = c2. An interesting
21
future research topic is to investigate the optimal ratio when the costs are related to the
true AUC parameters.
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APPENDIX
Appendix: variance derivation and proof of Proposition 1
Derivation of vAx and vAy
We can show that ∫ 1
0
∫ 1
0
[Sd{S
−1
d¯,1
(s), S−1
d¯,2
(t)}]dsdt
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can be expressed as
∫ ∞
−∞
∫ ∞
−∞
Sd(y1, y2)dSd¯,1(y1)dSd¯,2(y2).
Let S−1
d¯,1
(s) = y1 and S−1d¯,2(t) = y2, then, we have
∫ 1
0
∫ 1
0
[Sd{S
−1
d¯,1
(s), S−1
d¯,2
(t)}]dsdt = E[I(X1i > Y1j)I(X2i > Y2l)].
Similarly, vy becomes
vy =
2∑
ℓ=1
[∫ 1
0
∫ 1
0
rℓ(s)rℓ(t)(s ∧ t)dsdt−
{∫ 1
0
rℓ(s)sds
}2]
−2
∫ 1
0
∫ 1
0
r1(s)r2(t)[Sd¯{S
−1
d¯,1
(s), S−1
d¯,2
(t)} − st]dsdt.
It follows that
∫ 1
0
∫ 1
0
r1(s)r2(t)Sd¯{S
−1
d¯,1
(s), S−1
d¯,2
(t)}dsdt
=
∫ 1
0
∫ 1
0
S′
d,1
{S−1
d¯,1
(s)}
S′
d¯,1
{S−1
d¯,1
(s)}
S′
d,2
{S−1
d¯,2
(t)}
S′
d¯,2
{S−1
d¯,2
(t)}
Sd¯{S
−1
d¯,1
(s), S−1
d¯,2
(t)}dsdt.
Let S−1
d¯,1
(s) = y1 and S−1d¯,2(t) = y2, then it follows that
∫ ∫
S ′d,1{y1}S
′
d,2{y2}Sd¯(y1, y2))dy1dy2
=E[I(X1i < Y1j)I(X2k < Y2j)]
=E[(1− I(X1i > Y1j))(1− I(X2k > Y2j))]
=1−E(I(X1i > Y1j))− E(I(X2k > Y2j)) + E[I(X1i > Y1j)I(X2k > Y2j)].
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Because ∫ 1
0
∫ 1
0
r1(s)r2(t)stdsdt
can also be written as
1− Pr(X1i > Y1j)− Pr(X2k > Y2j) + E[I(X1i > Y1j)]E[I(X2k > Y2j)],
the expressions for vx and vy are simplified as follows:
vAx =
2∑
ℓ=1
(
E[I(Xℓi > Yℓj)I(Xℓi > Yℓl)]− [E(I(Xℓi > Yℓj))]
2
)
−2(E[I(X1i>Y1j)I(X2i>Y2l)]−E[I(X1i>Y1j)]E[I(X2i>Y2l)]) , (A.1)
and
vAy =
2∑
ℓ=1
(
E[I(Xℓi > Yℓj)I(Xℓk > Yℓj)]− [E(I(Xℓi > Yℓj))]
2
)
−2(E[I(X1i>Y1j)I(X2k>Y2j)]−E[I(X1i>Y1j)]E[I(X2k>Y2j)]) . (A.2)
✷
Proof of Proposition 1
We first prove that the proposition is true for the ∆-statistic. Similar arguments can
then be used for the Delong’s statistic. Let w¯ =
∑m1
i=1 wi
m1
. We see that in (4), wi’s are i.i.d.
random variables independent of i.i.d. random variables vj’s. It then follows that
cov
(∑m1+m2
i=1 wi
m1 +m2
, wi−w¯
)
=cov
(∑m1+m2
i=1 wi
m1 +m2
, wi
)
−cov
(∑m1+m2
i=1 wi
m1 +m2
, w¯
)
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equals 0, and
w¯ =
∫ 1
0
Sd,1(S
−1
d¯,1
(u))du−
1
m1
m1∑
i=1
∫ 1
0
I(X1i 6 S
−1
d¯,1
(u))du
+
1
m1
m1∑
i=1
∫ 1
0
I(X2i 6 S
−1
d¯,2
(u))du−
∫ 1
0
Sd,2(S
−1
d¯,2
(u))du.
We then get
(wi − w¯)=
1
m1
m1∑
i=1
∫ 1
0
I(X1i 6 S
−1
d¯,1
(u))du−
∫ 1
0
I(X1i 6 S
−1
d¯,1
(u))du
+
∫ 1
0
I(X2i 6 S
−1
d¯,2
(u))du−
1
m1
m1∑
i=1
∫ 1
0
I(X2i 6 S
−1
d¯,2
(u))du.
Therefore,
∑m1
i=1(wi − w¯)
2
m1 − 1
≈ vˆx1/m1,
which indicates that for large sample sizes, (
∑m1+m2
i=1 wi)/(m1 + m2) is independent
of vˆx,1/m1. Similarly, we get that for large sample sizes, (
∑n1+n2
j=1 vj)/(n1 + n2) is
independent of vˆy,1/n1. ✷
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Fig. 1. Optimal sampling ratio for comparing pAUCs. The observations are from two bivariate normal distributions.
The FPR is between 0 and 0.6.
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Table 1. Simulated power (in %) for comparing AUCs or pAUCs
Comparing AUCs using the DeLong’s method
Two-Stage r = 1 r = 0.5
ρ ΩA1 \ Ω
A
2 0.70 AR 0.75 AR 0.70 0.75 0.70 0.75
BN 0.75 79.3 1.001 - - 79.7 - 74.6 -
0.80 81.0 1.003 79.1 1.002 78.8 80.5 75.3 74.8
0.1 LN 0.75 80.5 1.001 - - 80.2 - 75.6 -
0.80 80.3 1.003 79.4 1.000 79.8 80.6 75.3 75.2
BE 0.75 81.0 1.340 - - 80.4 - 71.2 -
0.80 81.6 1.467 81.8 1.551 80.0 80.4 70.0 69.9
ΩA1 \ Ω
A
2 0.70 AR 0.75 AR 0.70 0.75 0.70 0.75
BN 0.75 79.8 1.002 - - 80.0 - 74.9 -
0.80 80.2 1.007 80.3 1.004 79.1 80.2 75.1 74.5
0.25 LN 0.75 79.8 1.002 - - 79.8 - 75.3 -
0.80 80.2 1.005 79.8 1.003 79.7 79.6 74.9 75.3
BE 0.75 83.7 1.412 - - 82.6 - 74.2 -
0.80 83.6 1.482 83.5 1.579 82.8 81.0 72.5 71.4
Comparing pAUCs using the ∆-statistic
Two-Stage r = 1 r = 0.5
ρ ΩPA1 \ Ω
PA
2 0.30 AR 0.35 AR 0.30 0.35 0.30 0.35
BN 0.35 79.2 0.952 - - 78.7 - 73.9 -
0.40 79.8 1.008 79.3 0.954 80.6 79.2 75.1 75.0
0.1 LN 0.35 79.0 0.953 - - 78.9 - 74.8 -
0.40 80.4 1.003 79.3 0.954 81.0 80.6 75.8 74.8
BE 0.35 84.6 1.249 - - 84.0 - 76.6 -
0.40 84.9 1.389 83.6 1.386 84.6 83.9 76.6 74.4
ΩPA1 \ Ω
PA
2 0.30 AR 0.35 AR 0.30 0.35 0.30 0.35
BN 0.35 78.7 0.947 - - 78.0 - 75.4 -
0.40 80.6 1.014 78.7 0.952 80.5 79.8 76.0 75.2
0.25 LN 0.35 79.2 0.949 - - 79.0 - 74.6 -
0.40 80.9 1.013 79.3 0.950 80.7 79.2 76.6 75.3
BE 0.35 86.9 1.219 - - 87.1 - 80.0 -
0.40 86.8 1.385 84.5 1.365 86.6 84.0 78.6 76.9
AR - the average ratio, BN - bivariate normal, LN - bivariate lognormal, BE - bi-
variate exponential, ΩA1 - the AUC for marker 1, ΩA2 - the AUC for marker 2, ΩPA1 - the
pAUC for marker 1, ΩPA2 - the pAUC for marker 2, ρ - the correlation coefficient of two
markers.
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Table 2. Type I error rates (in %) for comparing the AUCs or pAUCs
Comparing the AUCs Comparing the pAUCs
ρ AUCs N=200 400 500 pAUCs N=200 400 500
BN 0.70 4.5 5.8 5.0 0.30 5.6 5.9 4.6
0.75 5.4 5.8 4.0 0.35 6.8 5.8 5.0
0.80 5.3 5.1 5.2 0.40 6.7 5.5 6.1
LN 0.70 5.7 5.3 5.0 0.30 6.8 5.9 4.6
0.10 0.75 5.4 6.5 4.3 0.35 6.8 5.8 5.0
0.80 5.3 4.4 5.9 0.40 6.7 5.5 6.1
BE 0.70 5.4 5.1 4.4 0.30 6.2 5.4 5.5
0.75 5.3 6.6 4.0 0.35 7.7 7.4 5.6
0.80 5.2 5.1 4.3 0.40 7.5 7.3 5.0
BN 0.70 4.9 4.8 4.7 0.30 5.9 5.3 5.4
0.75 5.9 5.4 5.9 0.35 5.2 5.3 5.2
0.80 5.5 6.1 5.6 0.40 5.6 5.8 5.1
0.25 LN 0.70 5.2 5.3 5.5 0.30 6.0 5.3 5.4
0.75 5.9 5.4 5.9 0.35 5.2 5.3 5.2
0.80 5.8 3.9 4.3 0.40 6.7 5.8 5.4
BE 0.70 4.2 5.0 3.9 0.30 5.0 5.6 4.8
0.75 5.3 5.7 4.4 0.35 5.7 7.0 6.4
0.80 5.2 5.1 4.3 0.40 6.8 6.8 6.4
BN - bivariate normal, LN - bivariate lognormal, BE - bivariate exponential, N - the
total required sample size, ρ - the correlation coefficient of two markers
Table 3. Power comparison
m0(n0)
K 50 60 80 100
1 Ratio 1.02 1.01 0.87 1.07
Power (%) 31.9 26.6 32.6 33.7
10 Ratio 1.03 0.94 1.03 1.05
Power (%) 29.9 31.3 31.9 32.5
100 Ratio 1.03 1.02 1.00 1.03
Power (%) 31.1 30.8 31.1 31.4
K - the number of datasets simulated to estimate variances.
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